Machine learning, predictive models, and computational biology—how AI is changing discovery workflows and probability of success.
Generate Biomedicines said three posters tied to its AI-engineered anti-TSLP antibody GB-0895 were inadvertently made public ahead of a European Respiratory Society Congress embargo. The leak revealed new Phase 1 COPD and asthma findings and was followed by a stock pullback from the company’s Aug. 25 high.
Generate Biomedicines said three posters tied to its AI-engineered anti-TSLP antibody GB-0895 were inadvertently made public ahead of a European Respiratory Society Congress embargo. The leak revealed new Phase 1 COPD and asthma findings and was followed by a stock pullback from the company’s Aug. 25 high.
READ MORE
ProFound Therapeutics will receive $20 million upfront and could collect another $15 million in milestone payments to search placental tissue for biomarkers and drug targets in preeclampsia. The deal extends a partnering model built around proteomics data and AI-assisted target interpretation in an area with limited R&D investment.
An opinion piece from Autolomous’ CEO argues cell and gene therapy is still in a “pre-black box” phase, where fragmented data and limited sharing of failures slow learning across the field. The commercial signal is that AI may matter less as a standalone tool than as infrastructure for connecting development, manufacturing and post-treatment outcomes.
A BioSpace report describes a new class of AI-first drug developers attracting large financings even before disclosing candidates. The strategic signal is less about faster molecule generation alone than about using computation earlier to reduce development risk.
QuantHealth has raised $45 million to expand its AI platform for simulating clinical trials before patient enrollment, aiming to reduce failure rates and accelerate drug development timelines.
Grove AI, founded in 2024, leveraged advanced voice agent technology to streamline patient recruitment for clinical trials, leading to its rapid acquisition by Hippocratic AI.
As biopharma dealmaking increasingly hinges on access to advanced datasets, the question of who owns and controls AI-generated data is emerging as a major challenge for partnerships between Big Pharma and AI-driven biotech firms.
A new report by the Peterson Health Technology Institute finds gaps and complications in how healthcare systems pay for clinical AI, warning of projected cost increases and calls for reform.
Bristol Myers Squibb (BMS) stakes a bold claim with its plan to build the life sciences industry’s largest NVIDIA-powered AI supercomputer, continuing the pharma sector’s accelerating race into large-scale artificial intelligence infrastructure.
A new McKinsey report suggests that biopharma companies must reorganize their R&D departments to fully realize AI’s potential. Without foundational structural changes, the full benefits of artificial intelligence could remain out of reach for drug developers.
Xaira Therapeutics, once a stealthy newcomer, is starting to engage external partners as it looks to validate its ambitious AI-enabled drug discovery pipeline.
